Pradaxa
‘More than 2,000’ US lawsuits for Boehringer
February 14, 2014Sales and Marketing Boehringer, Pradaxa, Xarelto, blood thinner, warfarin
Boehringer Ingelheim is facing more than 2,000 lawsuits in the US over allegations that its stroke prevention pill Pradaxa has …
FDA has Xarelto concerns
July 2, 2013Sales and Marketing Bayer, Boehringer, FDA, Pradaxa, Xarelto
The FDA is unsure about an application to further extend the licence for Janssen and Bayer HealthCare’s blood thinner Xarelto …
German regulator assesses more drugs
April 22, 2013Sales and Marketing AMNOG, Bayer, Germany, Pradaxa, Xarelto
A new raft of drugs which will be subject to potentially stringent cost/benefit analysis in Germany has been announced. The …
Further indications for Eliquis
November 22, 2012Sales and Marketing BMS, Eliquis, NVAF, Pfizer, Pradaxa, Xarelto
Bristol-Myers Squibb and Pfizer’s oral blood-thinner Eliquis has been approved in Europe to prevent stroke in patients with nonvalvular atrial …
Further US approval for Xarelto
November 5, 2012Sales and Marketing Eliquis, FDA, Pradaxa, Xarelto
US regulators have given the go-ahead to expand the indications for which Janssen Pharmaceuticals and Bayer HealthCare’s oral blood thinner …
Eliquis receives nod in AF
September 24, 2012Sales and Marketing BMS, CHMP, Eliquis, Pfizer, Pradaxa, Xarelto
Bristol-Myers Squibb and Pfizer have received a boost with the CHMP’s recommendation that their co-marketed oral anticoagulant Eliquis should gain …
NICE yes for Xarelto to treat blood clots
July 25, 2012Sales and Marketing Bayer, DVT, NHS, NICE, Pradaxa, VTE, Xarelto
NICE is recommending Bayer’s Xarelto (rivaroxaban) for the treatment and prevention of deep vein thrombosis (DVT). The watchdog said in …
Priority review for Xarelto’s new indications
July 10, 2012Manufacturing and Production, Research and Development, Sales and Marketing Bayer, Boehringer, Eliquis, FDA, Janssen, Pradaxa, Xarelto
Xarelto is to be given a FDA fast-track review for a range of anti-blood clotting uses. Xarelto (rivaroxaban) gained its …
FDA rejects licence extension for Xarelto
June 26, 2012Sales and Marketing ACS, Bayer, FDA, J&J, JJ, Pradaxa, Xarelto
The FDA has set a Complete Response Letter to Bayer and J&J over its blood thinner Xarelto. The firms, which …
European OK for Pradaxa, but more details required
May 29, 2012Research and Development, Sales and Marketing Boehringer, CHMP, EMA, Europe, Pradaxa
The European Medicines Agency says that Boehringher’s Pradaxa can stay on the market, but will need more safety information. The …
NICE recommends Xarelto for stroke prevention
May 23, 2012Sales and Marketing Bayer, DVT, NICE, Pradaxa, Xarelto, anticoagulant
NICE is recommending Bayer’s anticoagulant pill Xarelto to help reduce the risk of stroke in certain patients. The watchdog’s final …
Petition launched to raise AF and stroke awareness
April 20, 2012Business Services, Medical Communications, Sales and Marketing AF, Boehringer Ingelheim, Pradaxa, Xarelto, stroke
Various health organisations have called on more people involved in the management of atrial fibrillation (AF) to help raise awareness …
NICE recommends Pradaxa for stroke prevention
March 15, 2012Sales and Marketing Boehringer Ingelheim, NICE, Pradaxa, atrial fibrillation
NICE has given a limited recommendation to Boehringer Ingelheim’s blood thinner Pradaxa. The watchdog said in final guidance that Pradaxa …
Boehringer censured over Pradaxa website
March 8, 2012Medical Communications ABPI, Boehringer Ingelheim, PMCPA, Pradaxa
Boehringer Ingelheim has breached the ABPI’s Code of Conduct over the use of its Pradaxa website. Pradaxa is a …
NICE set to reject Xarelto in AF
January 10, 2012Sales and Marketing AF, NICE, Pradaxa, Xarelto, atrial fibrillation
NICE says it needs more data on Bayer’s Xarelto in order to recommend it for people with atrial fibrillation. The …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
